The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of FGFR1 on epithelial-mesenchymal transition and EGFR resistance in HNC: A systems biology approach.
Damian Rieke
No relevant relationships to disclose
Zhixiang Zuo
No relevant relationships to disclose
Apoorva Chawla
No relevant relationships to disclose
Michaela K. Keck
No relevant relationships to disclose
Katharina Endhardt
No relevant relationships to disclose
Petra Fang
No relevant relationships to disclose
Arun Khattri
No relevant relationships to disclose
Johannes Braegelmann
No relevant relationships to disclose
Mark W. Lingen
No relevant relationships to disclose
Everett E. Vokes
Consultant or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis; Synta; VentiRx
Tanguy Y. Seiwert
Consultant or Advisory Role - Bayer/Onyx; Boehringer Ingelheim
Research Funding - Boehringer Ingelheim; Genentech; Novartis